

IN THE CLAIMS:

1. (Currently amended) A method of mitigating one or more symptoms associated with chronic consumption of a substance of abuse by a mammal, wherein said substance of abuse is alcohol, said method comprising:

administering to said mammal ~~[[an]]~~ a therapeutically effective amount of an adenosine receptor antagonist and ~~[[an]]~~ a therapeutically effective amount of a dopamine receptor antagonist;

wherein said therapeutically effective amount of the adenosine receptor antagonist is lower than said therapeutically effective amount of an adenosine receptor antagonist administered without said dopamine receptor antagonist ~~said administering of said adenosine receptor antagonist and said dopamine receptor antagonist enhances the potency of said adenosine receptor antagonist.~~

2.-145. (Canceled).

146. (Currently amended) The method of claim 1, wherein said therapeutically effective amount of the dopamine receptor antagonist is lower than said therapeutically effective amount of a dopamine receptor antagonist administered without said adenosine receptor antagonist ~~said administering of said adenosine receptor antagonist and said dopamine receptor antagonist enhances the potency of said dopamine receptor antagonist.~~

147. (Canceled)

148. (Previously Presented) The method of claim 1, wherein said dopamine receptor antagonist is administered at a standard therapeutic dosage.

149. (Previously Presented) The method of claim 1, wherein said dopamine receptor antagonist is administered at about a threshold dosage.
150. (Previously Presented) The method of claim 1, wherein said dopamine receptor antagonist is administered at a sub-threshold dosage.
151. (Previously Presented) The method of claim 1, wherein said adenosine receptor antagonist is administered at a standard therapeutic dosage.
152. (Previously Presented) The method of claim 1, wherein said adenosine receptor antagonist is administered at about a threshold dosage.
153. (Previously Presented) The method of claim 1, wherein said adenosine receptor antagonist is administered at a sub-threshold dosage.
154. (Canceled)
155. (Previously Presented) The method of claim 1, wherein said dopamine receptor antagonist is selected from the group consisting of butaclamol, chlorpromazine, domperidone, fluphenazine, haloperidol, heteroaryl piperidines, metoclopramide, olanzapine, perospirone hydrochloride hydrate, phenothiazine, pimozide, quetiapine, risperidone, sertindole, sulpiride, ziprasidone, and zotepine.
156. (Currently amended) The method of claim 1, wherein said therapeutically effective amount ~~dosage~~ of the dopamine receptor antagonist is sufficiently low so as to avoid causing an adverse symptom characteristically produced by administration of a dopamine receptor antagonist.
157. (Previously Presented) The method of claim 156, where said adverse symptom is

selected from the group consisting of tardive dyskensia, dystonia, and neuroendocrine (hormonal) disturbances.

158. (Previously Presented) The method of claim 1, wherein said adenosine receptor antagonist is selected from the group consisting of PD 115,199; ZM 241385, quinazoline, 3-(3-hydroxyphenyl)-5H-thiazolo[2,3b]-guinazoline, 1,3-diethyl-8-phenylxanthine, and substituted phenylxanthines.

159. (Currently amended) The method of claim 1, wherein said therapeutically effective amount ~~dosage~~ of the adenosine receptor antagonist is sufficiently low so as to avoid causing an adverse symptom characteristically produced by administration of an adenosine receptor antagonist.

160. (Previously Presented) The method of claim 159, where said adverse symptom is selected from the group consisting of sleep disorders, elevated heart rate, and arrhythmia.

161. (Previously Presented) The method of claim 1, wherein said dopamine receptor antagonist and said adenosine receptor antagonist are administered sequentially.

162. (Previously Presented) The method of claim 1, wherein said dopamine receptor antagonist and said adenosine receptor antagonist are administered simultaneously.

163. (Previously Presented) The method of claim 1, wherein said dopamine receptor antagonist and said adenosine receptor antagonist are administered in a single unit dosage formulation.

164. (Previously Presented) The method of claim 1, wherein said symptom is a chronic consumptive behavior.

165. (New) The method of claim 1, wherein said adenosine receptor antagonist is an adenosine A₂ receptor antagonist.

166. (New) The method of claim 1, wherein said dopamine receptor antagonist is a dopamine D₂ receptor antagonist.